Skip to content

The Application of Ketamine for Sedation in Patients With Cardiac Arrest - - KetCat (KETamine in Cardiac ArresT) Study

The Application of Ketamine for Sedation in Patients With Cardiac Arrest: Feasibility, Safety, and Potential Impact on Neurological Outcomes

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04360070
Acronym
KetCat
Enrollment
24
Registered
2020-04-24
Start date
2022-02-28
Completion date
2023-12-12
Last updated
2023-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Arrest, Out-Of-Hospital, Ketamine, Neurologic Manifestations

Keywords

Pilot Study, Single-Centre

Brief summary

Recent evidence suggests ketamine may attenuate harmful cellular cascades taking place after brain injury that result in permanent damage. The investigators are interested in researching the application of this in the setting of cardiac arrest. Following cardiac arrest, the brain is deprived oxygen for a period of time, leading to the imitation of these harmful cellular processes. The investigators hypothesize that patients who receive ketamine as part of their standard sedation procedures during cardiac arrest treatment have better neurological functioning compared to those who do not.

Interventions

DRUGKetamine Hydrochloride

Parenteral General Anesthetic

Sponsors

Fraser Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All out-of-hospital cardiac arrests (OHCA) with a shockable rhythm (ventricular fibrillation, pulseless ventricular tachycardia) that present to the Royal Columbian Hospital. The patient may be either in active cardiac arrest with shockable rhythm or may have achieved Return of Spontaneous Circulation (ROSC). * Over 19 years of age * Patients requiring sedation based on the assessment of the resuscitating physician.

Exclusion criteria

* Any other type of cardiac arrest * Any history of previous, pre-existing neurological deficit * Started on Extracorporeal Membrane Oxygenation (ECMO) * Duration of cardiac arrest without ROSC is greater than 30 consecutive minutes * Known contraindication or hypersensitivity to ketamine * Awake patient or no standard sedation or no intubation required * Inability to obtain deferred consent * Currently enrolled in any other research study involving drugs or devices * Patients who are pregnant * Patients who are prisoners * Patients residing in Long Term Care (LTC) facilities

Design outcomes

Primary

MeasureTime frameDescription
Feasibility Datathrough study completion, an average of 6 months.To test the appropriateness of the eligibility criteria by recording enrolment rates of eligible patients, test the randomization assignment procedures by evaluating for any difference in baseline characteristics between groups, and test adequate adherence to protocol by recording time taken to administer intervention during sedation procedures.

Countries

Canada

Contacts

Primary ContactGeorge Medvedev, MD
drmedvedev@shaw.ca604 759 2140

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026